Does the media favor ALNY or NBIX?

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 10 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.47 beat Alnylam Pharmaceuticals' score of 0.28 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BIIB or NBIX?

In the previous week, Biogen had 7 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 17 mentions for Biogen and 10 mentions for Neurocrine Biosciences. Biogen's average media sentiment score of 0.71 beat Neurocrine Biosciences' score of 0.47 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 10 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor UTHR or NBIX?

In the previous week, United Therapeutics had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 10 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.83 beat Neurocrine Biosciences' score of 0.47 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INCY or NBIX?

In the previous week, Incyte had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 13 mentions for Incyte and 10 mentions for Neurocrine Biosciences. Incyte's average media sentiment score of 0.78 beat Neurocrine Biosciences' score of 0.47 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to EXEL or NBIX?

In the previous week, Neurocrine Biosciences had 2 more articles in the media than Exelixis. MarketBeat recorded 10 mentions for Neurocrine Biosciences and 8 mentions for Exelixis. Neurocrine Biosciences' average media sentiment score of 0.47 beat Exelixis' score of 0.35 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Neurocrine Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neurocrine Biosciences (NBIX) Competitors

$174.26 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$174.72 +0.47 (+0.27%)

As of 07/2/2026 07:54 PM Eastern

Compare

NBIX vs. ALNY, BIIB, UTHR, INCY, and EXEL

Should you buy Neurocrine Biosciences stock or one of its competitors? MarketBeat compares Neurocrine Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Neurocrine Biosciences has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	11.24	$313.75M	$3.66	85.46
Neurocrine Biosciences	$2.86B	6.13	$478.60M	$6.49	26.85

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 10 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.47 beat Alnylam Pharmaceuticals' score of 0.28 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurocrine Biosciences has a net margin of 21.55% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Neurocrine Biosciences	21.55%	19.79%	13.82%

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Alnylam Pharmaceuticals presently has a consensus target price of $461.39, indicating a potential upside of 47.51%. Neurocrine Biosciences has a consensus target price of $187.52, indicating a potential upside of 7.61%. Given Alnylam Pharmaceuticals' higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Summary

Neurocrine Biosciences beats Alnylam Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Biogen?

Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

87.9% of Biogen shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Neurocrine Biosciences has a net margin of 21.55% compared to Biogen's net margin of 13.81%. Neurocrine Biosciences' return on equity of 19.79% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Biogen presently has a consensus target price of $217.41, indicating a potential upside of 0.60%. Neurocrine Biosciences has a consensus target price of $187.52, indicating a potential upside of 7.61%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	12 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.52
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.23	$1.29B	$9.32	23.19
Neurocrine Biosciences	$2.86B	6.13	$478.60M	$6.49	26.85

Biogen has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

In the previous week, Biogen had 7 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 17 mentions for Biogen and 10 mentions for Neurocrine Biosciences. Biogen's average media sentiment score of 0.71 beat Neurocrine Biosciences' score of 0.47 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	10 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neurocrine Biosciences beats Biogen on 12 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, United Therapeutics had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 10 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.83 beat Neurocrine Biosciences' score of 0.47 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

United Therapeutics presently has a consensus target price of $619.42, suggesting a potential upside of 11.42%. Neurocrine Biosciences has a consensus target price of $187.52, suggesting a potential upside of 7.61%. Given United Therapeutics' higher possible upside, research analysts plainly believe United Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Neurocrine Biosciences	21.55%	19.79%	13.82%

United Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.09	20.52
Neurocrine Biosciences	$2.86B	6.13	$478.60M	$6.49	26.85

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

United Therapeutics beats Neurocrine Biosciences on 12 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Incyte?

Incyte (NASDAQ:INCY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Incyte has higher revenue and earnings than Neurocrine Biosciences. Incyte is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.54	$1.29B	$7.08	16.51
Neurocrine Biosciences	$2.86B	6.13	$478.60M	$6.49	26.85

Incyte has a net margin of 26.71% compared to Neurocrine Biosciences' net margin of 21.55%. Incyte's return on equity of 26.66% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Incyte currently has a consensus price target of $107.85, suggesting a potential downside of 7.71%. Neurocrine Biosciences has a consensus price target of $187.52, suggesting a potential upside of 7.61%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

97.0% of Incyte shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

In the previous week, Incyte had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 13 mentions for Incyte and 10 mentions for Neurocrine Biosciences. Incyte's average media sentiment score of 0.78 beat Neurocrine Biosciences' score of 0.47 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Incyte beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

In the previous week, Neurocrine Biosciences had 2 more articles in the media than Exelixis. MarketBeat recorded 10 mentions for Neurocrine Biosciences and 8 mentions for Exelixis. Neurocrine Biosciences' average media sentiment score of 0.47 beat Exelixis' score of 0.35 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Neurocrine Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Neurocrine Biosciences	21.55%	19.79%	13.82%

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Exelixis has higher earnings, but lower revenue than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.05	$782.57M	$3.01	18.55
Neurocrine Biosciences	$2.86B	6.13	$478.60M	$6.49	26.85

Exelixis currently has a consensus price target of $47.60, suggesting a potential downside of 14.77%. Neurocrine Biosciences has a consensus price target of $187.52, suggesting a potential upside of 7.61%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Summary

Neurocrine Biosciences beats Exelixis on 12 of the 17 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBIX vs. The Competition

Export

Metric	Neurocrine Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.52B	$3.10B	$7.18B	$12.47B
Dividend Yield	N/A	2.05%	2.67%	6.51%
P/E Ratio	26.85	20.06	28.02	24.70
Price / Sales	6.13	357.08	534.82	99.70
Price / Cash	34.77	57.49	49.26	57.09
Price / Book	5.34	4.32	10.96	6.46
Net Income	$478.60M	$64.45M	$3.57B	$337.01M
7 Day Performance	3.41%	2.97%	2.12%	1.69%
1 Month Performance	6.33%	6.83%	5.25%	3.81%
1 Year Performance	36.10%	29.07%	33.29%	23.90%

Neurocrine Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBIX Neurocrine Biosciences	4.3943 of 5 stars	$174.26 flat	$187.52 +7.6%	+36.1%	$17.52B	$2.86B	26.85	2,000	Insider Trade Gap Down
ALNY Alnylam Pharmaceuticals	4.2422 of 5 stars	$286.41 +3.0%	$463.13 +61.7%	-5.8%	$37.13B	$3.71B	78.25	2,770	Analyst Revision Gap Down
BIIB Biogen	3.462 of 5 stars	$199.71 +1.6%	$217.37 +8.8%	+63.0%	$29.02B	$9.89B	21.43	7,500
UTHR United Therapeutics	4.5126 of 5 stars	$538.30 +0.3%	$619.42 +15.1%	+88.7%	$22.78B	$3.18B	19.87	1,400	Trending News Insider Trade
INCY Incyte	3.9867 of 5 stars	$103.66 +5.5%	$106.90 +3.1%	+70.7%	$19.62B	$5.14B	14.64	2,844	Options Volume Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. ALNY, BIIB, UTHR, INCY, and EXEL

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Summary

How does Neurocrine Biosciences compare to Biogen?

Summary

How does Neurocrine Biosciences compare to United Therapeutics?

Summary

How does Neurocrine Biosciences compare to Incyte?

Summary

How does Neurocrine Biosciences compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. ALNY, BIIB, UTHR, INCY, and EXEL

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Which has better earnings and valuation, ALNY or NBIX?

Does the media favor ALNY or NBIX?

Is ALNY or NBIX more profitable?

Do institutionals and insiders believe in ALNY or NBIX?

Which has more risk and volatility, ALNY or NBIX?

Do analysts rate ALNY or NBIX?

Summary

How does Neurocrine Biosciences compare to Biogen?

Do institutionals & insiders believe in BIIB or NBIX?

Is BIIB or NBIX more profitable?

Do analysts prefer BIIB or NBIX?

Which has better valuation & earnings, BIIB or NBIX?

Which has more volatility & risk, BIIB or NBIX?

Does the media prefer BIIB or NBIX?

Summary

How does Neurocrine Biosciences compare to United Therapeutics?

Does the media favor UTHR or NBIX?

Do analysts prefer UTHR or NBIX?

Is UTHR or NBIX more profitable?

Which has more volatility & risk, UTHR or NBIX?

Which has stronger earnings and valuation, UTHR or NBIX?

Do insiders and institutionals hold more shares of UTHR or NBIX?

Summary

How does Neurocrine Biosciences compare to Incyte?

Which has stronger valuation and earnings, INCY or NBIX?

Is INCY or NBIX more profitable?

Do analysts rate INCY or NBIX?

Do insiders and institutionals have more ownership in INCY or NBIX?

Which has more risk & volatility, INCY or NBIX?

Does the media prefer INCY or NBIX?

Summary

How does Neurocrine Biosciences compare to Exelixis?

Which has more volatility & risk, EXEL or NBIX?

Does the media refer more to EXEL or NBIX?

Is EXEL or NBIX more profitable?

Do institutionals and insiders have more ownership in EXEL or NBIX?

Which has higher valuation and earnings, EXEL or NBIX?

Do analysts prefer EXEL or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools